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Radionuclide Imaging
A Molecular Key to the Atherosclerotic Plaque
Harald F. Langer, MD,* Roland Haubner, PHD,† Bernd J. Pichler, PHD,‡ Meinrad Gawaz, MD*
Tübingen, Germany; and Innsbruck, Austria
Despite primary and secondary prevention, serious cardiovascular events such as unstable angina or myo-
cardial infarction still account for one-third of all deaths worldwide. Therefore, identifying individual patients
with vulnerable plaques at high risk for plaque rupture is a central challenge in cardiovascular medicine.
Several noninvasive techniques, such as magnetic resonance imaging, multislice computed tomography,
and electron beam tomography are currently being tested for their ability to identify such patients by mor-
phological criteria. In contrast, molecular imaging techniques use radiolabeled molecules to detect func-
tional aspects in atherosclerotic plaques by visualizing their biological activity. Based upon the knowledge
about the pathophysiology of atherosclerosis, various studies in vitro and in vivo and the first clinical trials
have used different tracers for plaque imaging studies, including radioactive-labeled lipoproteins, compo-
nents of the coagulation system, cytokines, mediators of the metalloproteinase system, cell adhesion re-
ceptors, and even whole cells. This review gives an update on the relevant noninvasive plaque imaging ap-
proaches using nuclear imaging techniques to detect atherosclerotic vascular lesions. (J Am Coll Cardiol
2008;52:1–12) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.03.036d
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mardiovascular diseases are the most frequent causes of death
n the Western world and represent a central challenge for
odern research and medicine. Rupture of the atherosclerotic
laque accounts for approximately 70% of fatal acute myocar-
ial infarctions and/or sudden coronary deaths (1). Throm-
otic complications, which arise from rupture or erosion of a
ulnerable plaque, may be clinically silent yet contribute to the
atural history of plaque progression and ultimately luminal
tenosis (1). Therefore, it seems to be essential to acquire
nformation beyond the resulting degree of stenosis detected by
ngiography. Over the past years, profound knowledge about
he mechanisms involved in atherogenesis was obtained due to
mbitious and excellent research. In the future, it is our
esponsibility to extend this knowledge by utilizing the field
f molecular plaque imaging to obtain new strategies to
etect vulnerable atherosclerotic plaques that cause critical
ardiovascular complications.
he “Vulnerable Plaque”
o identify apparently healthy subjects at risk for future
ardiovascular events, a consensus of experts has recently
rom the *Medizinische Klinik III, Eberhard Karls Universität Tübingen, Tübingen,
ermany; †Universitätsklinik für Nuklearmedizin, Medizinische Universität Inns-
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echnology, Clinic of Radiology, University of Tübingen, Tübingen, Germany. Dr.
anger is currently affiliated with the Experimental Immunology Branch, National
ancer Institute, National Institutes of Health, Bethesda, Maryland.m
Manuscript received January 18, 2008; revised manuscript received March 20,
008, accepted March 24, 2008.efined criteria for the diagnosis of “vulnerable plaques” (1).
esides minor criteria like calcified nodules, yellow appear-
nce of the plaque, or intraplaque hemorrhage, major
riteria have been established that represent different aspects
f the rupture-prone plaque (Fig. 1). Major criteria are
ctive inflammation, thrombogenicity, and plaque injury.
urther major criteria are related to plaque morphology and
nclude a thin cap, a large lipid core, or severe luminal
tenosis (1). Many groups have focused on anatomic imag-
ng modalities such as intravascular ultrasound, magnetic
esonance imaging (MRI), multislice computed tomogra-
hy (MSCT), and electron beam tomography to view the
ulnerable plaque (2–4).
Recent approaches using radionuclide imaging are
ased upon the pathophysiology of atherogenesis and
ave been evaluated to detect atherosclerotic lesions with
strong focus on the functional aspects of a plaque (Fig.
). The development of atherosclerotic plaques is a
rocess of complex, consecutive, and interacting steps
nvolving chemokines, the up-regulation of adhesion
olecules, recruitment of inflammatory cells to the arte-
ial wall, transmigration of these cells, and the develop-
ent of lipid-laden macrophages (the so-called foam
ells) from invading monocytes (5). As a result of these
rocesses, the early lesion of atherosclerosis—the fatty
treak—appears. Subsequently, more complex lesions de-
elop mediated by proliferation and migration of smooth
uscle cells and excessive production of extracellular
atrix proteins (5). Superficial erosions or fracture of the
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Radionuclide Imaging in Atherosclerosis July 1, 2008:1–12fibrous cap lead to plaque disrup-
tion followed by thrombus forma-
tion (6). Over the past years, dis-
tinct mediators and regulators
involved in the cascade of athero-
sclerosis have been identified,
which can be used to develop tools
for the detection and characteriza-
tion of atherosclerotic plaques by
means of noninvasive molecular
imaging (Table 1). The different
approaches include radionuclide-
labeled lipoproteins (7), compo-
nents of the coagulation system
(8), cytokines (9), mediators of the
matrix-metalloproteinase (MMP)
system (10), cell receptors (11),
and even whole cells (12). This
review gives an update on the rel-
evant noninvasive approaches in
plaque imaging with a focus on
radionuclide-based techniques to
detect vulnerable vascular lesions.
Nuclear Imaging Versus
Other Noninvasive
Modalities to Visualize the
Atherosclerotic Plaque
Coronary angiography has so far
been the gold standard to assess
narrowing of the vessel lumen.
Other invasive techniques have
been introduced that provide addi-
ional information for plaque characterization, including intra-
ascular coronary ultrasound, angioscopy, intravascular elastog-
Morphology
Inflammation
Stenosis Injury
Thrombogenicity
Proteolysis
Figure 1 Major Criteria Defining the “Vulnerable Plaque”
Vulnerable atherosclerotic plaques are characterized by distinct attributes
regarding morphology, stenosis, inflammation, thrombogenicity, injury, and
enhanced proteinase activity.
Abbreviations
and Acronyms
ApoE  apolipoprotein E
CT  computed
tomography
FCH  fluorocholine
FDG  fluorodeoxyglucose
GPVI  glycoprotein VI
LDL  low-density
lipoprotein
MCP  monocyte
chemoattractant protein
MDA2  malondialdehyde
epitope on oxidized low-
density lipoprotein
MMP  matrix
metalloproteinase
MRI  magnetic resonance
imaging
MSCT  multislice
computed tomography
NIRF  near-infrared
fluorescent
ox-LDL  oxidized low-
density lipoprotein
PET  positron emission
tomography
RGD  protein sequence
“arginine-glycine-aspartic
acid”
SPECT  single-photon
emission computed
tomography.Haphy, termography, or optical coherence tomography. All of
hese techniques have the disadvantage of being invasive.
oward the same end, increasing effort has been placed on
oninvasive imaging techniques. The 3 major modalities used
re MRI, MSCT, and nuclear imaging, each of them having
dvantages and disadvantages. In addition to stenosis detec-
ion, electron beam computed tomography (CT), dual source
dual energy), and MSCT are capable of picturing the coronary
rtery wall. By using MSCT, various components of the
therosclerotic wall may be distinguishable, allowing for iden-
ification of calcified areas or hypodensities, which correlate to
cholucent areas seen with intravascular ultrasound (13,14).
hile such hypodense areas are suggestive of lipid-rich
laques, differential diagnosis of such areas can include other
issue types such as less dense fibrous tissue. Thus, while
roviding a better spatial resolution than nuclear imaging
echniques, CT-based techniques may give less information on
istinct plaque components aside from the level of calcification.
sing MRI, T1- and T2-weighted imaging can provide in
itro information of the atheromatous core, collageneous cap,
nd calcifications (15). Although MRI provides good spatial
esolution, results at the coronary artery level have not yet been
onvincing, as the arteries are small, tortuous vessels in con-
inuous movement, which causes image aquisition difficulties.
Platelets
Apoptosis
Angiogenesis
Cell recruitment
Lipoproteins
ECM
Monocyte
Macrophage
Monocytes
Macrophages
L19                      
RGDLDL                                    
ox-LDL
MDA2                                                   
Annexin-V
Platelets
GPIIb-IIIa, GPVI                                                  
Fibrin                                                    
Collagen, fibronectin
Chemotaxis
MCP-1                
Metabolical
activity
FDG                               
FCH
Proteolysis
Plaque destabilization
MMPs
Cathepsin K                     
Thrombogenicity
Figure 2 Molecular Principles
to Detect Vulnerable Atherosclerotic Plaques
Based upon the increasing molecular knowledge regarding atherogenesis, dif-
ferent principles have been successfully used to image atherosclerotic
plaques. One major complex is the molecular imaging of inflammation, which
includes enhanced metabolic activity, chemotaxis, cell recruitment, and lipopro-
tein accumulation. Furthermore, mediators of angiogenesis, apoptosis, and
matrix metalloproteinase (MMP) activity have been successfully applied.
Another promising approach to detect vulnerable atherosclerotic plaque is the
visualization of plaque thrombogenicity, including thrombosis and exposure of
thrombogenic subendothelial matrix proteins. ECM  extracellular matrix; FCH
 fluorocholine; FDG  fluorodeoxyglucose; GP  glycoprotein; LDL  low-
density lipoprotein; L19  antibody against the extra-domain B of fibronectin;
MCP  monocyte chemoattractant protein; MDA2  malondialdehyde epitope
on oxidized low-density lipoprotein; ox-LDL  oxidized low-density lipoprotein;
RGD  protein sequence “arginine-glycine-aspartic acid.”owever, contrast-enhanced sequences have been tested and
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July 1, 2008:1–12 Radionuclide Imaging in Atherosclerosishown to improve the sensitivity of the method (16).
omputed tomography and MRI mainly provide informa-
ion based on morphology or anatomy.
The strength of nuclear imaging is its ability to provide
uantitative information on a functional level such as density of
specific receptor or the metabolic activity of a plaque. Nuclear
maging is based on radiolabeled biomarkers with a signal
ensitivity in the pico-molar range, which is 1 million to 1
illion times above that of MRI or CT. Thus, nuclear imaging
ay be the most promising approach for vulnerable plaque
etection. Currently, the leading modality in nuclear medicine
s positron emission tomography (PET), which acquires im-
ges with a spatial resolution up to 4 to 5 mm, thereby
mproving on the performance of single-photon emission
omputed tomography (SPECT), which has a resolution of 10
o 15 mm. To obtain good-quality images, the radiotracer
ust have rapid clearance from the bloodstream and a good
arget-to-background ratio. Given the small size of the plaque,
n which the radionuclide concentrates, a high background
ignal can impair the quality of PET or SPECT images. Thus,
he identification of promising highly specific molecular targets
ifferent Approaches to Visualize Atherosclerosis by Radionuclide I
Table 1 Different Approaches to Visualize Atherosclerosis by R
Underlying Plaque Biology Radionuclide Tracer
Inflammation 99mTc-LDL
Lipoprotein accumulation 123I-LDL
125I-LDL
99mTc-ox-LDL
123I-MDA2 (Ab to ox-LDL epitope)
125I-IK17 (Ab to ox-LDL epitope)
123I-SP4 (apoliprotein B fragment)
125I-SP4
Chemotaxis 125I-MCP-1 (chemotactic molecule)
Angiogenesis 125I-c(RGD(I)yV) (peptide binding v3)
99mTc-(NC100692) (peptide binding v3)
Monocyte recruitment/activity 111In-monocytes
18F-FDG (metabolic activity)
18F-FDG
18F-FDG
18F-FDG in comparison with 18F-FCH
VHSPNKK-modified magnetofluorescent nan
(VNP) (VCAM-1 expression)
Apoptosis 99mTc-annexin V (phosphatidylserine expres
99mTc-annexin V
99mTc-annexin V
99mTc-annexin V
Proteolysis 123I-HO-CGS27023 A (MMP inhibitor)
GHPGGPQKC-NH2 (cathepsin K substrate)—
Thrombogenicity and cell recruitment 111In-platelets
111In-platelets
125I-GPVI/123I-GPVI (platelet collagen recep
99mTc-DMP-444 (GPIIb-IIIa inhibitor)
99mTc-T2G1s Fab (fibrinogen binding)
125I-L19 (fibronectin binding)
CH  fluorocholine; FDG  fluorodeoxyglucose; GP  glycoprotein; HUVEC  human umbilical v
alondialdehyde epitope on oxidized low-density lipoprotein; MMP  matrix metalloproteinase;
arginine-glycine-aspartic acid”; VCAM  vascular cell adhesion molecule.s of central importance. Another problem that complicates amaging of coronary arteries is related to vessel anatomy and
eart pulsatility. Although the fast imaging protocols of MRI
r CT are advantageous over the relatively slow PET or
PECT imaging, modalities such as cardiac gating can im-
rove motion artefacts in cardiac imaging. Current research in
maging technology centers on the development of multimo-
ality scanners, such as PET/CT or more recently PET/MRI,
o provide comprehensive morphological and functional infor-
ation during 1 scan session. Such technical advance, in
articular PET/MRI, has enormous potential in the field of
ardiac imaging as it allows for simultaneous data acquisition,
hich is a huge improvement compared with the sequential
canning protocols of PET/CT. Although these approaches do
ot improve spatial resolution of the PET technique, they
rovide valuable information about the localization of the
cquired signal.
adionuclide Imaging of Plaque
etabolic activity. Atherosclerotic plaques are character-
zed by an accumulation of cells with high metabolic
ng
uclide Imaging
Experimental Setting Reference
Human carotid/ileofemoral artery Lees at al. 1988 (48)
Human carotid artery Virgolini et al. 1991 (53)
Rabbit aorta Virgolini et al. 1991 (54)
Human carotid artery Iuliano et al. 1996 (57)
Rabbit arteries Tsimikas et al. 1999 (49)
Mouse aorta Shaw et al. 2001 (50)
Rabbit aorta Hardoff et al. 1993 (51)
Rabbit aorta Lu et al. 1996 (52)
Rabbit aorta Ohtsuki et al. 2001 (9)
Murine ischemic hindlimbs/HUVECs Lee at al. 2005 (33)
Murine ischemic hindlimbs Hua et al. 2005 (47)
Human arteries Virgolini et al. 1990 (17)
Rabbit iliac artery Lederman et al. 2001 (18)
Human carotid artery Rudd et al. 2002 (20)
Human arteries Ben Haim et al. 2004 (19)
Mouse aortae Matter et al. 2007 (24)
icle Mouse carotid artery Kelly et al. 2005 (31)
Rabbit aorta Kolodgie et al. 2003 (72)
Human carotid artery Kietselaer et al. 2004 (70)
Swine coronary artery Johnson et al. 2005 (71)
Mouse aorta Isobe et al. 2006 (75)
Mouse carotid artery Schäfers et al. 2004 (10)
robe Mouse aortae and human carotid arteries Jaffer et al. 2007 (66)
Human carotid artery Minar et al. 1989 (76)
Human carotid artery Moriwaki et al. 1995 (77)
Mouse carotid artery Gawaz et al. 2005 (11)
Canine coronary artery Mitchel et al. 2000 (78)
Canine femoral/carotid artery Cerqueira et al. 1992 (79)
Mouse aorta Matter et al. 2004 (82)
othelial cell; LDL  low-density lipoprotein; MCP  monocyte chemoattractant protein; MDA2 
near-infrared fluorescent; ox-LDL  oxidized low-density lipoprotein; RGD  protein sequencemagi
adion
opart
sion)
NIRF p
tor)
ein endctivity. Therefore, various approaches addressed the prin-
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Radionuclide Imaging in Atherosclerosis July 1, 2008:1–12iple of metabolic activity to image atherosclerosis. Strate-
ies to find a feasible molecular target included the imaging
f metabolically active cells, metabolic substrates, or in-
reased uptake of molecules in active cells. One of the earlier
ttempts to visualize atherosclerotic lesions used 111In-
abeled patient-derived monocytes, which were reinjected,
nd relied on the presumption that these monocytes become
nvasive plaque macrophages (17). A more practical way to
mage metabolically active macrophages and inflammation
n general is the use of 18F-radiolabled fluorodeoxyglucose
18F-FDG) (18,19). Fluorodeoxyglucose competes with
lucose for uptake into metabolically active cells such as
acrophages, and it is already established in clinical practice
or imaging of tumors or for assessment of myocardial
iability. As this substance is therefore readily available, its
se is an attractive strategy for imaging atherosclerotic
esions, and several FDG-based studies have been carried
ut. In one instance for example, a clinical study successfully
mployed autoradiography to visualize 18F-FDG uptake in
acrophage-rich lesions of carotid endarterectomy speci-
ens ex vivo (20).
A recently published study suggested the use of alterna-
ive tracers that operate on a similar principle, namely
uorocholine (FCH). 18F-labeled fluorocholine (18F-FCH)
as been introduced as a tracer for imaging both brain and
rostate cancers. This choline derivative is taken up into
ells by specific transport mechanisms, phosphorylated by
holine kinase, metabolized to phosphatidylcholine, and
ventually incorporated into the cell membrane (21,22). The
ncreased choline uptake in highly proliferative cells such as
umor cells (23) and activated macrophages (22) has been
elated to an up-regulation of choline kinase as well as an
ncreased activity of choline-specific transporters (23). Cho-
ine kinase expression and activity seem to be similar in
ormal and atherosclerotic murine aortae (24). Thus, en-
anced 18F-FCH uptake in activated murine plaque mac-
ophages is not caused by changes in choline kinase, but
ather by increased choline transport (24). The rapid uptake
within 30 min) of 18F-FCH into inflammatory tissues
upports this notion (25,26). To demonstrate the relative
fficacy of 18F-FCH versus 18F-FDG, Matter et al. (24)
njected apolipoprotein E (ApoE)-deficient mice intrave-
ously with either tracer. En face measurements of aortae
solated 20 min after 18F-FCH injections demonstrated a
ery good correlation between fat stainings and autoradiog-
aphies achieving a sensitivity of 84% to detect plaques while
8F-FDG reached a lower sensitivity of 64% (24).
hemotaxis. In the early atherosclerotic plaque, chemo-
ines play an essential role, as they attract inflammatory cells
o the lesion and keep the inflammation process progressing
5). One strategy to image atherosclerotic plaques is, thus, to
isualize the expression of chemokines or their receptors
ithin the vascular wall. Similar to chemokines, adhesion
eceptors mediate the recruitment of inflammatory cells to
he atherosclerotic plaque. Thus, potential imaging strate- vies are to visualize chemokines, chemokine receptors or
dhesion receptors, or ligands.
Monocyte chemoattractant protein (MCP)-1 is one of
he strongest chemotactic agents, attracting inflammatory
ells to the atherosclerotic plaque (5,27). Although MCP-1
s not expressed in healthy vessels, various stimuli (e.g.,
umor necrosis factor and other cytokines) can induce the
xpression and secretion of MCP-1 in endothelial cells,
ascular smooth muscle cells, or cardiomyocytes, which by
riggering and sustaining leukocyte accumulation promote
nflammation (28). Elevated levels of circulating MCP-1
ave been found in patients with congestive heart failure
nd coronary artery disease and have been adversely corre-
ated with disease progression (29). Ohtsuki et al. (9)
nalyzed the localization of its receptor by using 125I-
CP-1 (half-time 10 min) in atheromas of cholesterol-
ed rabbits 4 weeks after arterial injury of the iliac artery and
he abdominal aorta. The activity of 125I-MCP-1 correlated
ith macrophage content per unit area as detected by
mmunohistochemistry using an antibody specific for rabbit
acrophages. Furthermore, ex-vivo autoradiography re-
ealed high 125I-MCP-1 activity within the vascular lesions.
long with chemotaxis, the up-regulation of adhesion
olecules on endothelial cells or leucocytes is also involved
n atherosclerotic inflammation. Recently, an established
eceptor ligand pair, vascular cell adhesion molecule
VCAM)-1 (endothelial cells) and very late antigen-4 (leu-
ocytes), has been used to visualize atherosclerotic plaques
30,31). Using a novel VCAM-1 peptide affinity ligand
dentified by phage display that was conjugated to a mag-
etofluorescent nanoparticle, atherosclerotic plaques were
isualized by MRI as the ligand was actively internalized by
CAM-1–expressing cells (31). While the number and
ange of studies are limited, the use of chemokines may be
promising candidate for noninvasive plaque imaging in
uture clinical practice.
ngiogenesis/v3 integrin. Accumulating evidence sug-
ests that the extent of neovascularization is closely linked
o the inflammatory reaction and infiltration of macro-
hages/foam cells within atherosclerotic plaques. A study of
69 advanced human atherosclerotic plaques concluded that
icrovessel formation is strongly correlated with both
laque rupture and the signature features of vulnerable
laques (32). So far, noteworthy studies have used 1
olecular target involved in the angiogenesis process, the
v3 integrin (33). This integrin is a heterodimeric trans-
embrane glycoprotein, which mediates cell/cell and cell/
atrix interactions, but is also involved in signal transduc-
ion from inside as well as outside the cell.
The v3 integrin is expressed on various cells originating
rom the mesenchyme and on a variety of cell types in the
lood vessel (including endothelial cells, smooth muscle
ells, fibroblasts, macrophages, and platelets). It is a pro-
iscuous integrin that binds to many different ligands
ncluding a number of extracellular matrix proteins such as
itronectin, fibronectin, osteopontin, fibrinogen, and von
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July 1, 2008:1–12 Radionuclide Imaging in Atherosclerosisillebrand factor, through the interaction with the Arg-
ly-Asp (RGD) motif (34,35). The v3 integrin is highly
xpressed in angiogenic or activated endothelial cells but
ot, or to a much lower extent, in quiescent endothelial cells
36,37).
Radioactive-labeled v3 antagonists and nuclear medi-
ine imaging techniques may provide a helpful tool to study
nd quantify angiogenetic processes in plaque development.
owever, most studies concerning tracer development and
valuation were carried out using tumor models (38). The
ajority of compounds described are based on the v-
elective cyclic pentapeptide with the amino acid sequence
yclo(-Arg-Gly-Asp-DPhe-Va-) (39). The type of tracer
howed comparable affinity and selectivity as the lead
tructure in vitro and receptor-specific accumulation in the
umor in vivo (40). However, the predominantly hepatobili-
ry elimination of the tracer demonstrated high activity
oncentrations in the liver and intestine. Thus, several
trategies to improve the pharmacokinetics of radiolabeled
eptides have been undertaken. They include conjugation
ith sugar moieties, hydrophilic amino acids, and polyeth-
lene glycol. The glycosylation approach (41,42), which is
ased on the introduction of sugar amino acids, resulted in
racers with good pharmacokinetic properties. In a murine
umor model, 18F-Galacto-RGD (RGD: 1 letter code for
he amino acids Arg-Gly-Asp, which are essential for
inding to the receptor) allowed noninvasive determination
f v3 expression in the tumor vasculature (Fig. 3) (43).
urrently, 18F-Galacto-RGD has been evaluated in a first
linical trial and demonstrates rapid predominant renal
xcretion and high metabolic stability resulting in good
umor/background ratios and, thus, high-quality imaging
43,44). Moreover, this initial study indicates that tracer
ccumulation correlates with v3 expression on blood
essels in the tumor lesions (Fig. 3). While a large set of
tudies demonstrating that the data concerning imaging
umor-induced angiogenesis can be translated to imaging,
he pathogenesis of plaque formation has yet to be com-
iled. Initial findings using v3-targeted nanoparticles and
agnetic resonance (45) as well as v3-targeted micro-
ubbles and contrast ultrasound imaging (46) indicate that
adiolabeled v3-targeted tracer may be used to define the
urden and evolution of atherosclerosis and the responsive-
ess of patients to corresponding therapies. Furthermore, a
ecent study employing a murine hindlimb ischemia model
llustrated that a 99mTc-labeled peptide (NC100692) targeted
o v3 integrin selectively localized to endothelial cells in
egions of increased angiogenesis and could be used for
oninvasive serial “hot spot” imaging of angiogenesis (47).
ipoproteins. Lipoproteins, particularly low-density li-
oproteins (LDLs), contribute substantially to early le-
ion formation. These mainly oxidized lipoproteins ini-
iate and sustain the inflammation process and are
ssential for foam cell generation (5). Strategies to utilize
he involvement of lipoproteins in atherogenesis include
he use of radiolabeled lipoproteins by themselves, detection tf epitopes within the lipoproteins (e.g., by the use of
adiolabeled antibodies) or radiolabeled endogeneous recep-
ors for lipoproteins (48–52). In initial studies, foam-cell-
ich early atherosclerotic lesions were detected by radiola-
eled autologous LDL molecules in both human and animal
tudies (53,54). Using a rabbit model of balloon-induced
theroma, Virgolini et al. (54) found a positive correlation
etween 125I uptake and the extent of foam cell infiltration.
owever, the use of radiolabeled LDL is not without
ifficulty as significant tracer activity appears within the
lood pool even several hours after injection and hampers
he detection of lipid-laden plaques. Further investigations
ave, therefore, focused on oxidized low-density lipoprotein
ox-LDL) or various epitopes of ox-LDL because of improved
laque-to-background ratio, the improved uptake into
acrophage-rich tissues, and the rapid clearance from the
lood pool. In addition, in this method there is no need to
btain autologous blood from the patients. Most of these
tudies have focused on malondialdehyde epitope on ox-
DL (MDA2), a radiolabeled murine monoclonal anti-
ody, which binds to the malondialdehyde epitope on
x-LDL, and there is a significantly higher uptake of
25I-MDA2 in lipid-rich lesions of atherosclerotic mice and
abbits compared with the uptake in healthy arteries
55,56). After dietary intervention, the same tracer was
uccessfully used to track changes in macrophage foam cell
ensity. In a clinical trial where 99mTc ox-LDL was used in
umans (57), tomographic scintigraphy of the neck in
atients suffering from transient ischemic attacks revealed
ccumulation of radiolabeled LDL preparations in the
arotid artery affected by atherosclerotic lesions. We have
ollowed a somewhat different approach. Mediating the
ptake of LDL, particularly ox-LDL, into macrophages
cavenger receptors (e.g., CD68, SR-A, CLA-1/SR-BI,
D36, LOX-1, and SR-PSOX) play a key role in athero-
clerotic lesion formation (Fig. 4A) (58). Thus, we conju-
ated 124I to the scavenger receptor CD68 (soluble CD68-
c) thereby using this molecule as our imaging probe.
D68 has been recently described to be important for foam
ell formation, as it binds ox-LDL, mediates its uptake (59),
nd may, therefore, be a useful tool for the detection of
therosclerotic plaques by the visualization of LDL (Fig.
B). In our study, wild type or ApoE/ mice (17 weeks
ld) were fed with a high cholesterol diet and injected with
190 Ci (7MBq) 124I-CD68-Fc, intravenously. After
8 h, animals were sacrificed and evaluated by ex vivo
utoradiography (Fig. 4C). In addition, sudan red staining
as performed to compare radioactivity with plaque forma-
ion (Fig. 4C). We found a good correlation of signal with
he extent of the lesion. While preliminary, our data suggest
hat CD68 is a potent molecular marker for the detection of
therosclerosis. These findings have to be verified by further
rofound investigations.
roteolysis. Through degradation of the extracellular ma-rix, proteases contribute to the progression and complica-
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Radionuclide Imaging in Atherosclerosis July 1, 2008:1–12ions of atherosclerotic lesions. At later stages of atheroscle-
osis, a lesion core is covered by a fibrous cap, which consists
ainly of smooth muscle cells and extracellular matrix and
eparates the lipid-rich core from the bloodstream (5).
Interstitial collagen molecules, adjacent to others like
brin, confer most of the tensile strength on the fibrous
ap, and several tightly regulated processes determine the
evels of collagen required for stability of this structure
6). Certain proinflammatory cytokines, such as interferon-
amma, can inhibit collagen production by smooth mus-
le cells, the principle source of this extracellular matrix
acromolecule in the arterial wall. Hence, the degree
Figure 3 Detection of Neoangiogenesis
(Top) (A) Coronal image section from a 18F-Galacto-RGD positron emission tomog
right axilla obtained 60 min after tracer injection. The image shows a clearly contr
almost all areas of the body. (B and C) Patient with a soft tissue sarcoma dorsal
tomography and the corresponding computed tomography scan shows that the reg
nonenhancing hypodense center shows no tracer uptake. (C) Immunohistochemis
onstrates intense staining predominantly of tumor vasculature. (Bottom) (D) Imm
strates that the squamous cell carcinoma of human origin do not express the v
3-subunit indicates that the tumor vasculature is v3-positive. (F and G) Transa
der acquired 90 min after 18F-Galacto-RGD injection show a clearly contrasting tum
tumor vasculature. Tracer accumulation can be blocked by injecting 18-mg cyclo
receptor-specific accumulation. Adapted from Haubner et al. (43).f plaque vulnerability is influenced by factors such as iverall size, core size, cap thickness, cap inflammation,
nd cap fatigue.
Enhanced turnover of the extracellular matrix is known to be
he reason for destabilization of the vulnerable fibrous cap. The
ells mainly responsible for this process are monocytes, which
ifferentiate to macrophages within the atherosclerotic lesion.
he destabilization is mediated by MMPs, which can be
eleased by activated macrophages, endothelial, and other
ascular cells. Known mediators of such inflammatory pro-
esses are tumor necrosis factor- and CD40L (60,61).
Strategies to image proteolytic activity included the use of
adiolabeled MMP inhibitors, substrates of MMPs, MMP
of a patient with a malignant melanoma and a lymph node metastasis at the
tumor and rapid predominately renal elimination with low background activity in
right knee joint. (B) The image fusion of the 18F-Galacto-RGD positron emission
f intense tracer uptake correspond with the enhancing tumor wall, whereas the
peripheral tumor section using the anti-v3 monoclonal antibody LM609 dem-
tochemical staining of tumor sections using the anti-v3 mAb LM609 demon-
rin. (E) In contrast, staining of sections with an antibody against the murine
ages of nude mice bearing a human squamous cell carcinoma at the right shoul-
e signal reflects tracer accumulation due to v3 expression exclusively in the
ly-Asp-DPhe-Val-) per kilogram mouse 10 min before tracer injection indicatesraphy
asting
of the
ions o
try of a
unohis
3 integ
xial im
or. Th
(-Arg-Gnhibitors, and cathepsins.
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July 1, 2008:1–12 Radionuclide Imaging in AtherosclerosisSchäfers et al. (10) used a broad-spectrum MMP inhib-
tor conjugated to 123I to develop the radioligand 123I-HO-
GS 27023A for in-vivo imaging of MMP activity. Four
eeks after induction of arterial injury in the carotid artery
f ApoE/ mice fed a cholesterol-rich diet, the tracer was
njected retro-orbitally, and uptake was measured. During
he first 2 h, a steadily increasing uptake could be detected.
pecificity was verified by predisposing cells with unlabeled
GS 27023A. A very elegant way to make use of enhanced
MP activity in tissues was recently published by Chen
t al. (62), who used a novel long-circulating, quenched
ear-infrared fluorescent (NIRF) probe, that is activated
y MMP-2 and -9, the essential proteases for the
athophysiology of atherosclerotic lesions. In vitro, the
uorescence signal changes can be detected after activa-
ion with MMP-2 or -9 at the specific wavelengths of the
ttached fluorochrome Cy5.5 by use of a fluorescence
late reader. For in vivo experiments, the authors chose a
ouse myocardial infarction model to monitor MMP
ctivity within the infarcted region. Near-infrared fluo-
escent imaging of MMP activity increased within 1 to 2
eeks after arterial ligation, a result that was confirmed
y parallel in-vitro methods including zymography and
everse transcription-polymerase chain reaction analysis
f MMP expression.
Choudhary et al. (63) used carotid endarterectomy spec-
Monocyte
Macrophage
Foam cell
Phagocytosis
Scavenger receptors
-CD68
-Lox-1
-SR-A
-CD36
-SR-BI
-CLA1
-SR-PSOX
-SR-BLH
A C
B
Human Fc
CD68
124I
Lipid Core
LDL
Figure 4 Detection of Atherosclerotic Plaques by Radiolabeled
(A) (Oxidized) lipoproteins initiate and sustain the inflammation process in atheros
ate the uptake of lipoproteins into macrophages and, thus, contribute substantiall
conjugated to an Fc-fragment was radiolabeled with 124I and used to detect athero
cholesterol diet for 17 weeks. Subsequently, mice were injected intravenously with
uate tracer activity in the aortic arch. Activity of 124ICD68-FC was enhanced in Apo
as shown by sudan red staining in the aortic arch specimen (top). LDL  low-densmen and multicontrast MRI to generate 3-dimensional ieconstructions and evaluate spatial distribution of MMPs
nd their inhibitors (tissue inhibitors of metalloproteinases)
n carotid atherosclerotic lesions. They found that their
istribution is highly heterogeneous and reflects lesion
ocation, size, and composition (63). Notably, the greater
bundance of MMP-9 in the plaque area suggests that it is
major MMP mediating remodeling in this area. In grossly
ormal areas, the level of total MMPs is lower and domi-
ated by MMP-2. The authors concluded that remodeling
f atheroma and normal arterial wall are mediated by
ifferent MMPs (63). The results are consistent with
revious observations that MMP-9, but not MMP-2, was
ecessary for organization of collagen by smooth muscle
ells (64).
In addition to MMPs, the cathepsin family of pro-
eases was tested for use in plaque imaging studies. Chen
t al. (65) optically imaged cathepsin B activity in
xperimental atherosclerosis in vivo using a NIRF ap-
roach. Similarly, Jaffer et al. (66) were able to visualize
therosclerotic plaques very recently in both mice and
umans using a NIRF imaging agent consisting of the
athepsin K peptide substrate (GHPGGPQKC-NH2)
inked to an activatable fluorogenic polymer. Taken
ogether, MMPs represent a very promising target for
oninvasive imaging, as they are essential for different
athophysiologic processes including tumor progression,
Wildtype ApoE-/-
sudan III staining
124I-CD68-Fc
8-Fc
ic lesions and are essential for foam cell generation. Scavenger receptors medi-
am cell formation. (B) A soluble dimeric form of the scavenger receptor CD68
sis in vivo. (C) Apolipoprotein E / (ApoE/) or wild type mice were fed a high
D68-Fc and sacrificed after 48 h. Ex-vivo nuclear imaging was performed to eval-
compared with wild type mice (bottom) and correlated well with plaque extension
oprotein.CD6
clerot
y to fo
sclero
124IC
E/
ity lipnflammation, and atherogenesis.
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Radionuclide Imaging in Atherosclerosis July 1, 2008:1–12poptosis. Apoptosis has been shown to be one of the
haracteristics of atherosclerotic plaques (67). Animal stud-
es of hypercholesterolemia showed both proliferation and
ell death of smooth muscle cells in early intimal lesions
68,69). Mentionable studies so far focused on annexin V
sing this molecule in a radiolabeled form (70). During the
rocess of apoptosis, phosphatidylserine, a phospholipid
ormally residing on the inner cell membrane of viable cells,
s externalized and, thus, available to affinity ligands such as
nnexin V.
In a model of porcine coronary atherosclerosis, apoptosis
f cells in the vascular wall of coronary arteries was detected
y SPECT using 99mTc-annexin V (71). Thirteen of 22
njured coronary vessels of animals receiving a high-fat
iet showed focal 99mTc-annexin V uptake. Another
roup made use of the same marker to detect experimen-
al atheroma in the aorta of balloon-injured rabbits in
ivo (72). In this study, histologically verified macro-
hage apoptosis showed a positive correlation with tracer
ptake. Several clinical studies using annexin V as a
adionuclide tracer have been carried out so far. In a study
ith 18 cardiac allograft recipients, 5 patients had posi-
ive myocardial uptake of annexin V (13 negative) (73).
s these 5 patients revealed at least moderate transplant
ejection and caspase-3 staining in the biopsy specimen,
he authors proposed the clinical feasibility of annexin V
maging for noninvasive detection of transplant rejection.
nother group also tried to visualize myocardial infarc-
ion by 99mTc-annexin V uptake (74), and in this trial 6
f 7 patients showed increased uptake of the tracer in
arly and late SPECT images. Lastly, a recent study
urther underlined the hypothesis that atherosclerotic
esions induced by a high-cholesterol diet in ApoE/
ice can be detected by apoptotic markers (75). Athero-
clerotic plaques in the aorta were visualized by 99man-
exin A5 using microSPECT and the quantitative uptake
f this tracer correlated with histological plaque extent
nd macrophage content (75). Despite these very prom-
sing results, further experimental and clinical studies
ave to be carried out to further establish the efficacy of
mploying nuclear imaging of programmed cell death for
oninvasive detection of the vulnerable atherosclerotic
laque.
hrombogenicity and cell recruitment. The majority of
yocardial infarctions are caused by development of a
hrombus in coronary vessels at the site of vascular lesions
erosion, plaque rupture) (Fig. 5A). Therefore, thromboge-
icity is a central feature of plaque vulnerability. A prereq-
isite for the formation of a thrombus is the exposure of
ubendothelial matrix components resulting in enhanced
ell recruitment. Plaque imaging approaches derived from
his principle include the use of cells participating in
hrombus formation, the detection of soluble coagulation
actors, or the visualization of exposed subendothelial
atrix. iEarly approaches used radionuclide-labeled platelets or
ater radionuclide-labeled platelet inhibitors to detect vul-
erable plaques (76–78). As the coagulation cascade results
n the development of a fibrin-rich thrombus, Cerqueira
t al. (79) used a radiolabeled monoclonal antibody frag-
ent 99mTc-T2G1s Fab, which is specific for fibrin, in a
anine carotid and femoral artery injury model. The tracer
as shown to bind twice as strong to trauma-induced
hrombotic arteries compared with arteries in sham-
perated animals (79). Another group also demonstrated
he feasibility of in vivo detection of acute and subacute
hrombosis using a fibrin-binding contrast agent in an
nimal model of atherosclerosis by an MRI approach (80).
plaque imaging study was performed using a F(ab=)2
onoclonal antibody (TRF1) against the human fragment
dimer of cross-linked fibrin for atherosclerotic plaques.
therosclerotic segments of carotid and femoral arteries of
patients and 5 control segments of atherosclerosis-free
nternal mammary arteries were drawn from 11 male pa-
ients undergoing bypass surgery (81). The 125I-TRF1
ntibody was used to distinguish atherosclerotic fragments,
atty streaks, and normal endothelium. The significantly
igher binding of TRF to atherosclerotic plaques compared
ith that in normal vessels was specific, as a control
ntibody showed no binding (81).
Within vulnerable atherosclerotic lesions, extracellular
atrix proteins like collagen or fibronectin are exposed that
re highly thrombogenic to circulating platelets and coagu-
ation but also represent potential targets for imaging
echniques. Matter et al. (82) used an 125I-labeled antibody
19, which targets the extradomain B of fibronectin and
njected atherosclerotic ApoE/ mice (82). By this ap-
roach, atherosclerotic plaques were detected after 3 days
ith signal-to-noise ratios of 105:1 at 3 days (82). Further-
ore, increased expression of extradomain-B domain in
uman atherosclerotic plaques can be detected by immuno-
istochemical studies. Our group has followed a similar
pproach by visualizing collagen exposed to blood flow.
etection of vulnerable plaques by radiolabeled platelet
lycoprotein VI (GPVI). We made use of the major
latelet collagen receptor GPVI, which plays a critical role
n the process of thrombosis at sites of atherosclerotic
esions. As the main extracellular matrix protein of arteries,
brillar collagen acts as a strong activator of platelets and
upports platelet-dependent thrombus formation (83,84).
ecently, platelet GPVI has been identified as the major
latelet collagen receptor in vivo (85). GPVI is a 60 to 65
DA type I transmembrane glycoprotein, which belongs to
he immunoglobulin superfamily (83). The soluble dimeric
orm of human GPVI conjugated to an Fc-fragment, which
as radioiodinated (Fig. 5B), was capable of detecting
esions of injured carotid arteries in mice through ex vivo
nd in vivo imaging (11). In 1 study, 5 min after induction
f injury, 124I-GPVI (or equivalent amounts of the radio-
odinated Fc-fragment as a negative control) was injected
ntravenously. An experimental mouse model of vascular
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July 1, 2008:1–12 Radionuclide Imaging in Atherosclerosisnjury was used, and wire-induced injury of the carotid
rtery was performed as described previously (86). In this
anner, vascular lesions were clearly detected with high
esolution using a dedicated small-animal PET scanner
MicroPET Focus 120, Siemens, Knoxville, Tennessee)
Fig. 5C), and images were matched with CT data (Fig.
C). The extent of the ex vivo autoradiography signal
orrelated with lesion formation as verified by lesion extent
n the explanted artery specimen (Fig. 5D). These experi-
ental data suggest that the soluble form of the platelet
ollagen receptor GPVI allows detection of thrombogenic
nd, thus, vulnerable arterial lesions.
Taken together, the thrombogenicity of atherosclerotic
laques is one of the most promising approaches to detect-
ng vulnerable plaques.
linical Perspective
he strength of molecular imaging is based on the fact
hat most diseases have an underlying biological basis
Blood flow
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Figure 5 Detection of Vulnerable, Thrombogenic Plaques by Ra
(A) Pathophysiology of platelet adhesion, secretion, and thrombus formation at sit
intact vessel, platelets do not adhere to the endothelial monolayer under physiolo
von Willebrand factor (vWF) and collagen are exposed to blood flow. Platelet adhes
platelets. 3) After activation of the integrins 21 (collagen receptor) and IIb3 (fi
cellular matrix proteins. 4) Subsequently, platelets get activated and secrete distin
IIb3 receptors and thrombus formation. (B) A soluble dimeric form of human pla
Glycoprotein VI is essential to establish the first interaction of platelets with an ex
thrombogenic and, thus, vulnerable plaques. (C and D) Apolipoprotein E/ mice
120, Siemens, Knoxville, Tennessee) (left). Images were acquired 24 h after adminis
images were correlated with computed tomographic (CT) data (right) to verify anatomi
imaging was performed to evaluate tracer activity in the aortic arch (top). The bottom
with plaque extension (left). The signal could be nearly abolished, when nonlabeled Ghat is not visualized by traditional imaging methods. eurthermore, it will most likely contribute to a person-
lized medicine by helping to tailor drug selection to an
ndividual’s proteome and genome (87). Imaging of
mportant molecular targets could transform clinical
anagement for diagnosis, risk stratification, selection,
nd efficacy assessment of molecule-based therapeutics. If
ethods are optimized, we may be able to decide which
atients harbor high-risk atherosclerotic plaques that will
ltimately cause myocardial infarction or stroke. Other
pplications include determining which post-myocardial
nfarction patients will develop pathological ventricular
emodeling and rapid progression to heart failure. Direct
isualization of the underlying biology in the diseased
issue may identify patients at high risk for cardiovascular
omplications, allowing the clinician to tailor disease
anagement on the basis of risk. Molecular imaging may
ot only identify patients at high risk for cardiovascular
vents (death, myocardial infarction, stroke) not identi-
ed by routine clinical evaluation (e.g., history, physical
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n receptor), platelets firmly adhere via interaction of these receptors with extra-
diators resulting in: 5) platelet aggregation via fibrinogen bridges between 2
PVI conjugated to an Fc-fragment was used, which was radiolabeled with 124I.
collagen surface. Therefore, we made use of this natural mechanism to detect
nalyzed with 124IGPVI-Fc using an animal microPET scanner (MicroPET Focus
of the tracer and imaging time was 20 min. Positron emission tomography (PET)
uctures. (C) Shows transverse sections of these experiments. (D) Ex vivo nuclear
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Radionuclide Imaging in Atherosclerosis July 1, 2008:1–12rotein, exercise treadmill testing), but also the charac-
erization of lesion vulnerability in high-risk areas of the
oronary vasculature (e.g., the proximal one-third of each
f the coronary arteries [88]) may be possible. Once the
esion has been determined to be of particularly high risk,
ovel local therapies such as intracoronary drug-eluting
tents or local drug delivery with suitable drug-delivery
alloon catheters could be justified. At present, the
election of many target-specific therapeutics depends on
opulation-based studies or randomized clinical trials.
hese approaches, however, do not routinely assess the
iological variability of the disease process in individual
atients. Thus, molecular plaque imaging will help to
elect individualized treatment strategies based on the
olecular profile of vulnerable plaques identified in
articular patients. In keeping with this, several promis-
ng atherosclerosis-targeted imaging agents have already
ndergone testing in the clinic or are on the clinical
orizon (Fig. 6) (87).
onclusions
ver the past years, clinical data and observations have
mphasized the need for a more profound characterization
f atherosclerotic plaques. It is essential to acquire informa-
ion beyond the resulting degree of stenosis detected by
ngiography. Epidemiologic studies have shown that a
ANT
L
A
C Transverse
Transverse
Coronal
Coronal
Figure 6 Molecular Imaging of Apoptosis in Atherosclerosis Us
Technetium-99m labeled annexin A5 accumulates in unstable atherosclerotic plaq
recent transient ischemic attack. (B) Annexin A5 in sections of the resected plaqu
(C) appears in the carotid artery of a patient with a transient ischemic attack 3 m
corresponding smooth-muscle-cell-rich lesion. Images provided courtesy of Dr. Bas
lands. Reprinted, with permission, from Kietselaer et al. (70).onsiderable amount of patients with sudden cardiac eventsave no alarming symptoms before a serious event (89).
urthermore, acute coronary syndromes often result from
laque rupture at sites with no or only moderate luminal
arrowing detected by angiography (90,91). Molecular im-
ging of atherosclerotic plaques offers new strategies to
etect vulnerable atherosclerotic plaques that are prone to
hrombus formation. Increasing our knowledge about the
olecular biology of plaque vulnerability and identification
f new mediators will prove most promising and challenging
nd will propel the field of plaque imaging to the forefront
f cardiology.
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